Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Opendoor Technologies to Perform

Oppenheimer Downgrades Opendoor Technologies to Perform

Oppenheimer analyst Jason Helfstein downgrades Opendoor Technologies (NASDAQ:OPEN) from Outperform to Perform.

byBenzinga Newsdesk

February 27, 2023

1 minute read

Oppenheimer analyst Jason Helfstein downgrades Opendoor Technologies (NASDAQ:OPEN) from Outperform to Perform.

Keybanc Maintains Overweight on Hayward Holdings, Lowers Price Target to $14

By Benzinga Newsdesk

October 13, 4:32 AM

Keybanc analyst Jeffrey Hammond maintains Hayward Holdings (NYSE:HAYW) with a Overweight and lowers the price target from $16 to $14.

HAYW

Democratic Senators Ask Office Of Comptroller Of The Currency To Replace Cryptocurrency Guidance

By Michael Horton

August 10, 12:52 PM

-Reuters

BITF

News

Bristol Myers Squibb Announced Earlier., Investigational LPA1 Antagonist Reduces Rate Of Lung Function Decline In Progressive Pulmonary Fibrosis Cohort Of Phase 2 Study

By Charles Gross

September 9, 8:24 PM

Bristol Myers Squibb (NYSE:BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist in patients with progressive

BMY

Analyst Ratings

9 Analysts Have This to Say About Integra Lifesciences

By Benzinga Insights

July 28, 8:00 AM

Integra Lifesciences (NASDAQ:IART) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

IART

Oppenheimer Downgrades Opendoor Technologies to Perform

Related Posts

Keybanc Maintains Overweight on Hayward Holdings, Lowers Price Target to $14

Democratic Senators Ask Office Of Comptroller Of The Currency To Replace Cryptocurrency Guidance

Bristol Myers Squibb Announced Earlier., Investigational LPA1 Antagonist Reduces Rate Of Lung Function Decline In Progressive Pulmonary Fibrosis Cohort Of Phase 2 Study

9 Analysts Have This to Say About Integra Lifesciences